Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode… Read More ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Amgen, Gilead and Vertex all show up in the same note, but the bank isn't treating them equally.

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside. Read more on ...

Scientists at the Department of Energy's Oak Ridge National Laboratory have created a platform that pinpoints genetic ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t ...

A transatlantic partnership gives biotech startups lower-cost access to lab equipment while reducing waste and Scope 3 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...

Effective translation of the benefits of NRDL inclusion: 3 indications of 佳泰莱® and 达泰莱® have been included in the 2025 NRDL, which officially took effect on January 1, 2026. This marks 佳泰莱® the only ...